Detail of the clinical trial
| Title of the trial | A phase 3, multicenter, randomized, open-label, study of Azacitidine (Vidaza) versus conventional care regimens for the treatment of older subjects with newly diagnosed acute myeloid leukemia |
|---|---|
| EudraCT number | 2009-012346-23 |
| Protocol number | AZA-AML-001 |
| Sponsor | Celgene Corporation, Summit, USA |
| Indications | Hemato-oncology |
| Diagnosis | acute myeloid leukemia |
| Population in clinical trial |
Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2010 |
| Date of approval by Institute (SÚKL) | 14.7.2010 |
| Date of approval by EC | 14.7.2010 |
| Date of initiation CT in ČR | 26.4.2011 |
| Date of ending CT in ČR | 25.3.2014 |
| Notice | |
| Sites |
Ústav hematologie a krevní transfuse, U Nemocnice, Praha 2 I. interní klinika hematoonkologie VFN a 1. LF UK, U Nemocnice, Praha 2 Interní hematoonkologická klinika, FN Brno Hemato-onkologická klinika, FN Olomouc |
cz